TIDMAGL
Angle PLC
09 November 2023
For immediate release 9 November 2023
ANGLE plc ("the Company")
ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIES
ANGLE's Portrait PD-L1 test uses CTCs harvested from the
Parsortix system to investigate real-time patient PD-L1 status for
clinical studies
The test is designed for highly accurate, repeatable, and
precise results for CTC PD-L1 biomarker expression
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumour cell (CTC) diagnostic
solutions for use in research, drug development and clinical
oncology, is delighted to announce the launch of its Portrait(R)
PD-L1 test for the evaluation of PD-L1 protein expression on CTCs
following extensive development and optimisation. The test is
provided as a service from ANGLE's Onc-ADaPT(R) GCP-compliant
laboratories and is conducted by an expert team with over 10 years'
experience in CTC analysis.
PD-L1 is an immune-related biomarker that can be expressed on
the surface of tumour cells across a range of cancer types, and
expression of this biomarker enables cancer cells to evade immune
response mechanisms that would typically keep abnormal cell growth
in check. Consequently, PD-1/PD-L1 inhibitors have emerged as the
leading immunotherapy treatment option with over 2,800 active
interventional studies in progress involving 430,000 patients.
The output of current tumour tissue-based PD-L1 tests varies
considerably, with poor performance often unavoidable due to the
elapsed time between tissue biopsy (generally taken at diagnosis
and difficult or impossible to repeat) and disease progression
(which may be months or years later) when immunotherapies are
considered, during which time PD-L1 status can change. ANGLE has
developed its immunofluorescence (IF) based test for the
determination of PD-L1 status on CTCs to allow real-time assessment
of biomarker status, which may address this fundamental flaw in
current PD-L1 tests via a simple blood test.
ANGLE's Portrait PD-L1 service is an end-to-end solution using
ANGLE's world leading Parsortix CTC technology to deliver:
-- minimally invasive liquid biopsy with sample stability up to five days post-blood collection
-- biomarker independent harvest of phenotypically diverse CTCs from a simple blood test
-- identification and enumeration of CTCs with accurate, precise assessment of PD-L1 status (see https://angleplc.com/onc-adapt-laboratories/portrait-pd-l1/ )
-- longitudinal monitoring of PD-L1 status over multiple time
points including before, during and after the patient receives the
treatment.
It is well established that the number of CTCs is prognostic of
cancer treatment response, recurrence, and relapse and this has
been documented in numerous peer-reviewed publications. It is now
evident that changes in CTC numbers and their PD-L1 status can
provide an early indication of immunotherapy treatment resistance
and progressive disease. Studies have also shown that CTCs isolated
from patients with solid cancers and expressing PD-L1 may serve as
a clinically actionable biomarker for immunotherapy.
The global PD-1 and PD-L1 immunotherapy market is currently
valued at US $36.9 billion per annum, and analysts predict the
market to reach US $109.1 billion by 2032. Despite the rapid
expansion of the immunotherapy market, with many indications
approved under accelerated approval, this class of drug has been
challenged by the withdrawal of a range of indications due to the
failure to subsequently confirm the clinical benefit in such
indications in larger trials. As such, a test that can help with
patient stratification in biopharmaceutical drug trials, and act as
an early predictor of treatment response and disease recurrence
could provide earlier insight into critical efficacy endpoints.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"Whilst immune checkpoint inhibitors have achieved remarkable
progress in tumour treatment, the cost of treatment is high and
currently the majority of patients fail to respond.
ANGLE's Portrait PD-L1 test provides accurate, repeatable, and
precise PD-L1 identification on CTCs and hence has the potential to
streamline patient selection and optimise PD-L1 monitoring for
treatment response and disease progression throughout clinical
studies.
We are now beginning an active promotion of this test to
biopharma customers."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora, Alexander Ind +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology using a simple
blood sample. ANGLE's FDA cleared and patent protected circulating
tumour cell (CTC) harvesting technology known as the Parsortix(R)
PC1 System enables complete downstream analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories. Services include custom made assay development and
clinical trial testing for pharma.
Over 80 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAVVLFBXFLLFBQ
(END) Dow Jones Newswires
November 09, 2023 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
過去 株価チャート
から 4 2024 まで 5 2024
Angle (LSE:AGL)
過去 株価チャート
から 5 2023 まで 5 2024